| Identification | Back Directory | [Name]
A 71915 | [CAS]
132956-87-7 | [Synonyms]
A 71915
A-71915TFA
RC-{Cyclohexyl-Ala}-GGRIDRI-{d-Tic}-RC
H-Arg-Cys-b-cyclohexyl-Ala-Gly-Gly-Arg-Ile-Asp-Arg-Ile-D-Tic-Arg-Cys-NH2
(Arg6,b-cyclohexyl-Ala8,D-Tic16,Arg17,Cys18)-Atrial Natriuretic Factor (6-18) aMide (Mouse, rabbit, rat)
(Arg6,β-cyclohexyl-Ala8,D-Tic16,Arg17,Cys18)-Atrial Natriuretic Factor (6-18) amide (mouse, rabbit, rat)
10H-[1,2,5,8,11,14,17,20,23,26,29,32,35]Dithiaundecaazacyclooctatriacontino[11,10-b]isoquinoline,cyclic peptide deriv
(Arg,β-cyclohexyl-Ala,D-Tic1,Arg1,Cys1)-Atrial Natriuretic Factor (6-18) amide (mouse, rabbit, rat) trifluoroacetate salt
L-Cysteinamide, L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-α-aspartyl-L-arginyl-L-isoleucyl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-arginyl-, cyclic (2→13)-disulfide | [Molecular Formula]
C69H117N25O16S2 | [MDL Number]
MFCD00672741 | [MOL File]
132956-87-7.mol | [Molecular Weight]
1616.97 |
| Chemical Properties | Back Directory | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
4.00±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Soluble to 1 mg/ml in water | [Sequence]
Arg-Cys-{Cha}-Gly-Gly-Arg-Ile-Asp-Arg-Ile-{d-Tic}-Arg-Cys-NH2 (Disulfide bridge: Cys2-Cys13) |
| Hazard Information | Back Directory | [Description]
A 71915 is an atrial natricuretic factor receptor antagonist. It blocks physiological effects of angiotensin. | [Uses]
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pKi= 9.18). A 71915 displaces [125I]ANP dose dependently, with a Ki of 0.65 nM. A71915( pA2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells[1]. | [in vivo]
A 71915 (5 μl; i.m.; 25-30 g male CD-1 mice) affects BNP (1 nmol)- and GRP (0.1 nmol)-induced scratching[2].
A 71915 (30 μg/ kg/ day) inhibits NS-398 on blood pressure decreased[3]. | Animal Model: | Rat (Male Sprague-Dawley); weighing 150-180 g[3] | | Dosage: | 30 μg/kg/day; infused for 3 weeks | | Administration: | via a mini-osmotic pump | | Result: | The inhibitory effect of NS-398 on blood pressure was attenuated by the pretreatment with A 71915 (30 μg/kg/day). |
| [storage]
Store at -20°C | [References]
[1] Delporte C, et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol. 1992;224(2-3):183-188. DOI:10.1016/0014-2999(92)90803-c
[2] Kiguchi N, et al. Spinal Functions of B-Type Natriuretic Peptide, Gastrin-Releasing Peptide, and Their Cognate Receptors for Regulating Itch in Mice. DOI:10.1124/jpet.115.229997
[3] Park BM, et al. Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release. Peptides. 2015;69:1-8. DOI:10.1016/j.peptides.2015.03.022 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|